<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="22%"></col>
<col width="35%"></col>
<col width="42%"></col>
<tbody>
<tr>
<td align="center" stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drug/Drug Class (Mechanism of Interaction by the Drug) </content>
</paragraph>
</td>
<td align="center" stylecode="Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Voriconazole Plasma Exposure <br/>(C<sub>max</sub> and AUC</content>
<sub>τ</sub>
<content stylecode="bold"> after 200 mg q12h) </content>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Rifampin* and Rifabutin*</paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Efavirenz (400 mg q24h)** (CYP450 Induction) <br/>
<br/>Efavirenz (300 mg q24h)** (CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Reduced <br/>
<br/>
<br/>
<br/>Slight Decrease in AUC<sub>τ</sub>
</paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated <br/>
<br/>
<br/>
<br/>
</content>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>High-dose Ritonavir (400 mg q12h)** (CYP450 Induction)<br/>
</paragraph>
<paragraph>Low-dose Ritonavir (100 mg q12h)** (CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
<paragraph>
<br/>
<br/>
<br/>Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
<paragraph>
<br/>
<br/>
<br/>Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Carbamazepine </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Long Acting Barbiturates </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Not Studied<content stylecode="italics"> In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Phenytoin* </paragraph>
<paragraph>(CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg) </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>St. John’s Wort </paragraph>
<paragraph>(CYP450 inducer; P-gp inducer) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Reduced </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Oral Contraceptives**</paragraph>
<paragraph>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Increased </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>Significantly Increased </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole </paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule Botrule " valign="top">
<paragraph>Other HIV Protease Inhibitors </paragraph>
<paragraph>(CYP3A4 Inhibition) </paragraph>
</td>
<td align="center" stylecode="Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure<br/>
</paragraph>
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </paragraph>
</td>
<td align="center" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with <br/>indinavir<br/>
<br/>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors </paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule Lrule " valign="top">
<paragraph>Other NNRTIs***</paragraph>
<paragraph>(CYP3A4 Inhibition or CYP450 Induction) </paragraph>
</td>
<td align="center" stylecode="Botrule Lrule " valign="top">
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)<br/>
</paragraph>
<paragraph>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole </paragraph>
<paragraph>Careful assessment of voriconazole effectiveness </paragraph>
</td>
</tr>
</tbody>
</table>